European journal of medicinal chemistryHumansEstrogen Receptor alphaBreast NeoplasmsCell ProliferationAntineoplastic Agents
Highly potent and selective degrader targeting ERα to improve the treatment outcomes of breast cancer.
Xueting Bao, Xunkai Yin, Jinjing Xu, ZhenZhen Zhu, Wenyu Lu, Yihui Cai, Rupeng Dai, Zhe Zheng, Wenzhuo Xu, Shulan Mei, Songyun Xu, Jie Li, Nianguang Li, Haohao Zhu, Jianing Wang
Published: 202610.1016/j.ejmech.2025.118199
Abstract
Estrogen receptor alpha (ERα) is overexpressed in approximately 70 % of breast cancer cases; therefore, it is considered a primary therapeutic target for breast cancer. Several therapeutic agents, including selective estrogen receptor modulators, aro…
Preview only. Read the full abstract at the source